DEF: Definitive Healthcare Corp. Announces 2025 Annual Meeting of Stockholders, Outlines Key Proposals

Definitive Healthcare Corp. is set to hold its 2025 Annual Meeting of Stockholders on June 5, 2025, to vote on the election of directors, ratification of the independent auditor, and executive compensation.

Summary

• Definitive Healthcare Corp. will hold its Annual Meeting of Stockholders on June 5, 2025, in Framingham, MA.
• Stockholders of record as of April 14, 2025, are eligible to vote.
• The meeting will address the election of three Class I directors, the ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation.
• The Board recommends voting FOR the election of the director nominees, FOR the ratification of Deloitte & Touche LLP, and FOR the advisory vote on executive compensation.
• The proxy materials were first sent or made available to stockholders on or about April 23, 2025.
• The company's performance in 2024 fell short of expectations due to decreased renewal rates and operational disruption.
• Revenue was $252.2 million, a 0.3% increase year-over-year.
• Annual Recurring Revenue (ARR) decreased by 3% to over $245 million.
• Adjusted EBITDA was $79.1 million, representing 31% of revenue.
• The company reported a GAAP Net loss of $(591.4) million, inclusive of a $688.9 million goodwill impairment charge.

Sentiment

Score: 5

Explanation: The document presents a mixed sentiment. While there are positive aspects like increased Adjusted EBITDA, the overall tone is weighed down by the significant net loss and underperformance against expectations. The forward-looking statements offer some optimism, but the current financial results temper the positive outlook.

Positives

• Adjusted EBITDA increased to $79.1 million, or 31% of revenue, compared to $74.5 million, or 30% of revenue, for the full year 2023.

Negatives

• The company's performance in 2024 fell short of expectations due to decreased renewal rates and operational disruption.
• Annual Recurring Revenue (ARR) decreased by 3% to over $245 million.
• GAAP Net loss was $(591.4) million, including a $688.9 million goodwill impairment charge.

Risks

• Decreased renewal rates from existing customers attributed to both life science conditions and disruption in the medical and prescription claims supply chain.
• Operational disruption related to both Company restructuring and executive transitions.
• Challenges in forecasting reliable and meaningful longer-term performance targets.

Future Outlook

The company believes it is taking the right actions for the long term to capitalize on its leadership position in a large and attractive market, with a strategy designed to return it to predictable revenue growth, Adjusted EBITDA profitability, and capital efficiency.

Management Comments

• Kevin Coop, Chief Executive Officer, expressed gratitude for stockholders' continued support.
• Management believes they are taking the right actions for the long term to capitalize on their leadership position in a large and attractive market.

Industry Context

The document references peer companies within the health care technology, application software, and interactive media and services industry groups, suggesting Definitive Healthcare operates within these sectors.

Comparison to Industry Standards

• The document compares Definitive Healthcare's executive compensation to a peer group including companies like Amplitude, Health Catalyst, Certara, and Veeva Systems.
• The selection criteria for the peer group included industry, size (annual revenues ranging from approximately $60 million to $2 billion), and business characteristics (focus on healthcare, SaaS technology, and analytics/intelligence solutions).
• The document also mentions the use of industry-specific survey data to determine pay levels for NEOs.

Management Changes

Corporate Governance

Related Party Transactions

• The document discloses a master services agreement with Encora Digital, LLC, where Advent (a holder of more than 5% of Definitive Healthcare's voting securities) owns a majority voting interest.
• The company committed to pay Encora approximately $1.7 million pursuant to the master services agreement over a one-year period beginning in November 2024.

Stakeholder Impact

• The election of directors will impact the leadership and oversight of the company, affecting strategic direction and governance.
• The advisory vote on executive compensation allows shareholders to express their views on the company's pay practices.
• The financial performance of the company directly impacts shareholder value and employee compensation.

Next Steps

• Stockholders are encouraged to vote by proxy before the Annual Meeting.
• The Board and the Human Capital Management and Compensation Committee intend to consider the results of the advisory vote on executive compensation in future determinations.

Key Dates

Keywords

Annual Meeting, Proxy Statement, Executive Compensation, Board of Directors, Deloitte & Touche, Director Election, Financial Performance, ARR, Adjusted EBITDA, Governance